表紙
市場調查報告書

局部皮膚適用製劑製造前25家分析:2019年

Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies

出版商 Visiongain Ltd 商品編碼 863490
出版日期 內容資訊 英文 176 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
局部皮膚適用製劑製造前25家分析:2019年 Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies
出版日期: 2019年04月15日內容資訊: 英文 176 Pages
簡介

2018年的全球局部皮膚適用製劑的市場預計成長到262億3000萬美元的規模。

本報告提供全球局部皮膚適用製劑的市場調查,市場概要,主要企業概要,收益的變化、預測,提供產品,開發平台趨勢,近幾年的發展等資訊彙整。

第1章 報告概要

第2章 主要企業

  • Galderma (Nestle Skin Health S.A.)
  • Johnson & Johnson (J&J)
  • AbbVie, Inc.
  • GlaxoSmithKline, plc (GSK)
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Valeant Pharmaceuticals (Bausch Health Companies Inc.)
  • Almirall S.A.
  • Eli Lilly and Company
  • Mylan N.V.
  • Lupin Ltd.
  • Novartis AG
  • Sanofi
  • Allergan plc.
  • Merck
  • Sun Pharmaceutical Industries, Ltd.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Mayne Pharma
  • Concert Pharmaceuticals, Inc.
  • Novan, Inc.
  • Bayer AG
  • Astellas Pharma Inc.
  • Pierre Fabre, S.A.
    • 收益預測
    • 產品系列
    • 產品平台
    • 近幾年的發展等

第3章 總論

目錄
Product Code: PHA0380

Dermatological drugs market has been growing over the last decade. A combination of significant new market launches, and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain's analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 176-page report you will receive 108 tables and 71 figures- all unavailable elsewhere.

The 176-page report provides clear detailed insight into the top 25 dermatological drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

  • Assessment of the leading companies in the global dermatological drugs market. The list below shows some of the companies that are discussed in the report:
  • Abbvie Inc.
  • Allergan plc
  • Almirall S.A.
  • Amgen
  • Astellas
  • Bayer
  • Concert Pharmaceuticals
  • Eli Lilly and Company
  • Galderma
  • GlaxoSmithkline plc (GSK)
  • Johnson & Johnson (J&J)
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma
  • Other companies
  • For each company, the report provides information and discussion on:
  • Total revenue forecast to 2028
  • Dermatology segment revenue forecast to 2028
  • The leading dermatology drugs revenue forecast to 2028
  • Drugs portfolio
  • Recent developments
  • The report provides revenue forecast to 2028 for the following dermatological drugs:
  • Epiduo
  • Differin
  • Stelara
  • Remicade
  • Humira
  • Valtrex
  • Lamisil
  • Bactroban
  • Dermovate
  • Zyvox
  • Protopic
  • Solodyn
  • Ziana
  • Taltz
  • Cosentyx
  • Aczone
  • Cubicin
  • Elocon
  • Absorica /Epirus
  • Enbrel
  • Doryx
  • Canesten
  • Bepanthen/Bepanthol
  • Key questions answered by this report:
  • How is the Dermatological Drugs Manufacturers market evolving?
  • What is driving and restraining the Dermatological Drugs Manufacturers market?
  • What will be the main driver for the overall market to 2028?
  • Will leading Dermatological Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?

Visiongain's study is intended for anyone requiring commercial analyses for the Top 25 Dermatological Drugs Manufacturers 2019. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Why You Should Read This Report
  • 1.2 How the Study Delivers
  • 1.3 Main Questions Covered in the Analysis
  • 1.4 Who is this Report For?
  • 1.5 Methods of Research and Analysis
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Market Evaluation and Forecasting Methods
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Reports
  • 1.8 About Visiongain

2. Leading Companies in the Dermatological Drugs Market 2019

  • 2.1 Dermatological Drugs - A Rapidly Consolidating Market
  • 2.2 Galderma (Nestle Skin Health S.A.)
    • 2.2.1 Galderma (Nestle Skin Health S.A.): Total Revenue Forecast to 2028
    • 2.2.2 Galderma (Nestle Skin Health S.A.): Dermatology Revenue Forecast to 2028
    • 2.2.3 Galderma: Dermatological Drugs Portfolio, 2018
    • 2.2.4 Global Leading Dermatological Drugs Galderma
      • 2.2.4.1 Epiduo
        • 2.2.4.1.1 Epiduo: Revenue Forecast to 2028
      • 2.2.4.2 Differin
        • 2.2.4.1.2 Differin: Revenue Forecast to 2028
    • 2.2.5 Galderma: Recent Developments
      • 2.2.5.1 Nestlé's Acquisition of Galderma
      • 2.2.5.2 Approval and Launch of Soolantra for Rosacea
      • 2.2.5.3 FDA Approval of Restylane Lyft for Hands
      • 2.2.5.4 Collaboration between Janssen's and Galderma's Nordic affiliates
  • 2.3 Johnson & Johnson (J&J)
    • 2.3.1 Johnson & Johnson: Total Revenue Forecast to 2028
    • 2.3.2 Johnson & Johnson: Dermatology Revenue Forecast to 2028
    • 2.3.3 Johnson & Johnson: Dermatological Drugs Portfolio, 2018
    • 2.3.4 Global Leading Dermatological Drugs Johnson & Johnson
      • 2.3.4.1 Stelara
        • 2.3.4.1.1 Stelara: Revenue Forecast to 2028
      • 2.3.4.2 Remicade
        • 2.3.4.2.1 Remicade: Revenue Forecast to 2028
    • 2.3.5 Johnson & Johnson: Recent Developments
      • 2.3.5.1 U.S. FDA Approval of Tremfya (Guselkumab)
      • 2.3.5.2 New TREMFYA (GUSELKUMAB) Data Demonstrates Long-Term Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
      • 2.3.5.3 Extended Indication U.S. FDA Approval of STELARA (ustekinumab)
  • 2.4 AbbVie, Inc.
    • 2.4.1 AbbVie, Inc.: Total Revenue Forecast to 2028
    • 2.4.2 AbbVie, Inc.: Dermatology Revenue Forecast to 2028
    • 2.4.3 AbbVie, Inc.: Dermatological Drugs Portfolio, 2017
    • 2.4.4 Global Leading Dermatological Drug AbbVie: Humira
      • 2.4.4.1 Humira: Revenue Forecast to 2028
    • 2.4.5 AbbVie, Inc.: Dermatological Drugs Product Pipeline, 2018
    • 2.4.6 AbbVie, Inc.: Recent Developments
      • 2.4.6.1 AbbVie Announces HUMIRA (adalimumab) Patent License with Mylan
      • 2.4.6.2 AbbVie and Calico Announce Extension of Ground-breaking Collaboration
      • 2.4.6.3 AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
  • 2.5 GlaxoSmithKline, plc (GSK)
    • 2.5.1 GlaxoSmithKline, plc (GSK): Total Revenue Forecast to 2028
    • 2.5.2 GlaxoSmithKline, plc (GSK): Dermatology Revenue Forecast to 2028
    • 2.5.3 GlaxoSmithKline, plc. (GSK): Dermatological Drugs Portfolio, 2017
    • 2.5.4 Global Leading Dermatological Drug Glaxosmithkline
      • 2.5.4.1 Valtrex
        • 2.5.4.1.1 Valtrex: Revenue Forecast to 2028
      • 2.5.4.2 Lamisil
        • 2.5.4.2.1 Lamisil: Revenue Forecast to 2028
      • 2.5.4.3 Bactroban
        • 2.5.4.3.1 Bactroban: Revenue Forecast to 2028
      • 2.5.4.4 Dermovate
        • 2.5.4.4.1 Dermovate: Revenue Forecast to 2028
    • 2.5.5 GlaxoSmithKline, plc. (GSK): Dermatological Drugs Product Pipeline, 2018
    • 2.5.6 GlaxoSmithKline, plc. (GSK): Recent Developments
      • 2.5.6.1 GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
      • 2.5.6.2 Business Restructuring Arrangements with Novartis
      • 2.5.6.3 Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
  • 2.6 Pfizer, Inc.
    • 2.6.1 Pfizer, Inc.: Total Revenue Forecast to 2028
    • 2.6.2 Pfizer, Inc.: Dermatology Revenue Forecast to 2028
    • 2.6.3 Pfizer, Inc.: Dermatological Drugs Portfolio, 2018
    • 2.6.4 Global Leading Dermatological Drug Pfizer
      • 2.6.4.1 Zyvox
        • 2.6.4.1.1 Zyvox: Revenue Forecast to 2028
    • 2.6.5 Pfizer, Inc.: Dermatological Drugs Product Pipeline, 2018
    • 2.6.6 Pfizer, Inc.: Recent Developments
      • 2.6.6.1 XELJANZ (Tofacitinib Citrate) receives marketing authorisation in the European Union for active psoriatic arthritis
      • 2.6.6.2 Pfizer to expand venture investing with $600 Million commitment to Pfizer ventures
      • 2.6.6.3 Pfizer receives breakthrough therapy designation from FDA for PF-04965842, an oral JAK1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis
  • 2.7 LEO Pharma A/S
    • 2.7.1 LEO Pharma A/S: Total Revenue Forecast to 2028
    • 2.7.2 LEO Pharma A/S: Dermatology Revenue Forecast to 2028
    • 2.7.3 LEO Pharma A/S: Dermatological Drugs Portfolio, 2018
    • 2.7.4 Global Leading Dermatological Drugs LEO Pharma
      • 2.7.4.1 Protopic
        • 2.7.4.1.1 Protopic: Revenue Forecast to 2028
    • 2.7.5 LEO Pharma A/S: Dermatological Drugs Product Pipeline, 2018
    • 2.7.6 LEO Pharma A/S: Recent Developments
      • 2.7.6.1 LEO Pharma A/S to expand its lead in medical dermatology with acquisition of Bayer's prescription dermatology unit
      • 2.7.6.2 LEO Pharma A/S begins phase 3 clinical study with tralokinumab in adolescent patients with moderate-to-severe atopic dermatitis
      • 2.7.6.3 LEO Pharma A/S and FibroTx LLC enter partnership to explore non-invasive skin test technology
  • 2.8 Valeant Pharmaceuticals (Bausch Health Companies Inc.)
    • 2.8.1 Valeant Pharmaceuticals: Total Revenue Forecast to 2028
    • 2.8.2 Valeant Pharmaceuticals: Dermatology Revenue Forecast to 2028
    • 2.8.3 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Dermatological Drugs Portfolio, 2018
    • 2.8.4 Global Leading Dermatological Drug Valeant Pharmaceuticals
      • 2.8.4.1 Solodyn
        • 2.8.4.1.1 Solodyn: Revenue Forecast to 2028
      • 2.8.4.2 Ziana
        • 2.8.4.2.1 Ziana: Revenue Forecast to 2028
    • 2.8.5 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Dermatological Drugs Product Pipeline, 2018
    • 2.8.6 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Recent Developments
      • 2.8.6.1 Bausch Health Companies Inc. completes name change
      • 2.8.6.2 Valeant Down as FDA Refuses to Approve Duobrii for Psoriasis
      • 2.8.6.3 Valeant Announces U.S. Launch of SILIQ (brodalumab) Injection
  • 2.9 Almirall S.A.
    • 2.9.1 Almirall S.A.: Total Revenue Forecast to 2028
    • 2.9.2 Almirall S.A.: Dermatology Revenue Forecast to 2028
    • 2.9.3 Almirall S.A.: Dermatological Drugs Portfolio, 2018
    • 2.9.4 Almirall S.A.: Dermatological Drugs Product Pipeline, 2018
    • 2.9.5 Almirall S.A.: Recent Developments
      • 2.9.5.1 Transformational Transaction - Almirall to acquire US medical dermatology portfolio from Allergan
      • 2.9.5.2 Almirall receives positive CHMP opinion for new anti IL23 tildrakizumab for the treatment of patients with moderate-to-severe chronic plaque psoriasis Almirall
  • 2.10 Eli Lilly and Company
    • 2.10.1 Eli Lilly and Company: Total Revenue Forecast to 2028
    • 2.10.2 Eli Lilly and Company: Dermatology Revenue Forecast to 2028
    • 2.10.3 Eli Lilly and Company: Dermatological Drugs Portfolio, 2018
    • 2.10.4 Global Leading Dermatological Drug Eli Lilly: Taltz
      • 2.10.4.1 Taltz: Revenue Forecast to 2028
    • 2.10.5 Eli Lilly and Company: Dermatological Drugs Product Pipeline, 2018
    • 2.10.6 Eli Lilly and Company: Recent Developments
      • 2.10.6.1 Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
      • 2.10.6.2 Lilly Completes Acquisition of ARMO BioSciences
  • 2.11 Mylan N.V.
    • 2.11.1 Mylan N.V.:Total Revenue Forecast to 2028
    • 2.11.2 Mylan N.V.: Dermatology Revenue Forecast to 2028
    • 2.11.3 Mylan N.V.: Dermatological Drugs Portfolio, 2018
    • 2.11.4 Mylan N.V.: Recent Developments
      • 2.11.4.1 Mylan to Bring a Biosimilar of BOTOX to the Market through a Collaboration and License agreement with Revance Therapeutics, Inc.
      • 2.11.4.2 Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
      • 2.11.4.3 Mylan Completes Acquisition of Meda
  • 2.12 Lupin Ltd.
    • 2.12.1 Lupin Ltd.: Total Revenue Forecast to 2028
    • 2.12.2 Lupin Ltd.: Dermatology Revenue Forecast to 2028
    • 2.12.3 Lupin Ltd.: Dermatological Drugs Portfolio, 2018
    • 2.12.4 Lupin Ltd.: Dermatological Drugs Product Pipeline, 2018
    • 2.12.5 Lupin Ltd.: Recent Developments
      • 2.12.5.1 Lupin launches generic Desoximetasone Topical Spray, 0.25% in the US
      • 2.12.5.2 Lupin and Mylan Partner to Commercialize Enbrel (Etanercept) Biosimilar
      • 2.12.5.3 Lupin submits New Drug Application for Etanercept biosimilar in Japan
  • 2.13 Novartis AG
    • 2.13.1 Novartis AG: Total Revenue Forecast to 2028
    • 2.13.2 Novartis AG: Dermatology Revenue Forecast to 2028
    • 2.13.3 Novartis AG: Dermatological Drugs Portfolio, 2018
    • 2.13.4 Global Leading Dermatological Drug Novartis: Cosentyx
      • 2.13.4.1 Cosentyx: Revenue Forecast to 2028
    • 2.13.5 Novartis AG: Dermatological Drugs Product Pipeline, 2018
    • 2.13.6 Novartis AG: Recent Developments
      • 2.13.6.1 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
      • 2.13.6.2 Sandoz receives European Commission approval for biosimilar Hyrimoz (adalimumab)
      • 2.13.6.3 Sandoz receives European Commission approval for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases
  • 2.14 Sanofi
    • 2.14.1 Sanofi: Total Revenue Forecast to 2028
    • 2.14.2 Sanofi: Dermatology Revenue Forecast to 2028
    • 2.14.3 Sanofi: Dermatological Drugs Portfolio, 2018
    • 2.14.4 Sanofi: Recent Developments
      • 2.14.4.1 Sanofi and Advent finalize negotiations for the acquisition of Zentiva
      • 2.14.4.2 Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
      • 2.14.4.3 Dupixent (dupilumab) showed positive Phase-3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
      • 2.14.4.4 Demand for Dupixent remains strong
  • 2.15 Allergan plc.
    • 2.15.1 Allergan plc.: Total Revenue Forecast to 2028
    • 2.15.2 Allergan plc.: Dermatology Revenue Forecast to 2028
    • 2.15.3 Allergan plc.: Dermatological Drugs Portfolio, 2018
    • 2.15.4 Global Leading Dermatological Drug Allergan
      • 2.15.4.1 Aczone
        • 2.15.4.1.1 Aczone: Revenue Forecast to 2028
    • 2.15.5 Allergan plc.: Dermatological Drugs Product Pipeline, 2018
    • 2.15.6 Allergan plc.: Recent Developments
      • 2.15.6.1 FDA Accepts New Drug Application for Seysara (Sarecycline) for the Treatment of Moderate to Severe Acne
      • 2.15.6.2 ACZONE (dapsone) Gel, 7.5% Recognized with Teen Vogue Acne Award Win
      • 2.15.6.3 Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
  • 2.16 Merck
    • 2.16.1 Merck: Total Revenue Forecast to 2028
    • 2.16.2 Merck: Dermatology Revenue Forecast to 2028
    • 2.16.3 Merck: Dermatological Drugs Portfolio, 2018
    • 2.16.4 Global Leading Dermatological Drug Merck
      • 2.16.4.1 Cubicin
        • 2.16.4.1.1 Cubicin: Revenue Forecast to 2028
      • 2.16.4.2 Elocon
        • 2.16.4.2.1 Elocon: Revenue Forecast to 2028
    • 2.16.5 Merck: Recent Developments
      • 2.16.5.1 Merck and Viralytics Announce Acquisition Agreement, Expanding Merck's Leading Immuno-Oncology Pipeline
      • 2.16.5.2 Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology
      • 2.16.5.3 Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
  • 2.17 Sun Pharmaceutical Industries, Ltd.
    • 2.17.1 Sun Pharmaceutical Industries, Ltd.: Total Revenue Forecast to 2028
    • 2.17.2 Sun Pharmaceutical Industries, Ltd.: Dermatology Revenue Forecast to 2028
    • 2.17.3 Sun Pharmaceutical Industries, Ltd.: Dermatological Drugs Portfolio, 2018
    • 2.17.4 Global Leading Dermatological Drug Sun Pharmaceutical
      • 2.17.4.1 Absorica /Epirus
        • 2.17.4.1.1 Absorica /Epirus: Revenue Forecast to 2028
    • 2.17.5 Sun Pharmaceutical Industries, Ltd.: Recent Developments
      • 2.17.5.1 Sun Pharma Announces U.S. FDA Approval of ILUMYA (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
      • 2.17.5.2 Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab
      • 2.17.5.3 Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan
  • 2.18 Amgen Inc.
    • 2.18.1 Amgen Inc.: Total Revenue Forecast to 2028
    • 2.18.2 Amgen Inc.: Dermatology Revenue Forecast to 2028
    • 2.18.3 Amgen Inc.: Dermatological Drugs Portfolio, 2018
    • 2.18.4 Global Leading Dermatological Drug Amgen: Enbrel
      • 2.18.4.1 Enbrel: Revenue Forecast to 2028
    • 2.18.5 Amgen Inc.: Dermatological Drugs Product Pipeline, 2018
    • 2.18.6 Amgen Inc.: Recent Developments
      • 2.18.6.1 Amgen Announces Top-Line Results from Phase 3 Study of ABP 710, Biosimilar Candidate to Infliximab
      • 2.18.6.2 Amgen Launches the ENBREL Mini Single-Dose Prefilled Cartridge with AutoTouch Reusable Autoinjector That Is Ergonomically Designed for Patients
      • 2.18.6.3 Amgen and CytomX Therapeutics Announce Strategic Collaboration in Immuno-Oncology
  • 2.19 F. Hoffmann-La Roche Ltd
    • 2.19.1 F. Hoffmann-La Roche Ltd: Total Revenue Forecast to 2028
    • 2.19.2 F. Hoffmann-La Roche Ltd: Dermatology Revenue Forecast to 2028
    • 2.19.3 F. Hoffmann-La Roche Ltd: Dermatological Drugs Portfolio, 2018
  • 2.20 Mayne Pharma
    • 2.20.1 Mayne Pharma: Total Revenue Forecast to 2028
    • 2.20.2 Mayne Pharma: Dermatology Revenue Forecast to 2028
    • 2.20.3 Mayne Pharma: Dermatological Drugs Portfolio, 2018
    • 2.20.4 Global Leading Dermatological Drugs Mayne Pharma
      • 2.20.4.1 Doryx
        • 2.20.4.1.1 Doryx: Revenue Forecast to 2028
    • 2.20.5 Mayne Pharma: Recent Developments
      • 2.20.5.1 Mayne Pharma acquires generic EFUDEX, Complementing US Dermatology Portfolio
      • 2.20.5.2 Mayne Pharma announces FDA approval and immediate launch of Doxycycline Hyclate IR tablets, first generic to Acticlate
      • 2.20.5.3 Mayne Pharma launches Fabior and Sorilux in the UNITED STATES
  • 2.21 Concert Pharmaceuticals, Inc.
    • 2.21.1 Concert Pharmaceuticals, Inc.: Total Revenue Forecast to 2028
    • 2.21.2 Concert Pharmaceuticals, Inc.: Dermatology Revenue Forecast to 2028
    • 2.21.3 Concert Pharmaceuticals, Inc.: Recent Developments
      • 2.21.3.1 Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement
      • 2.21.3.2 Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds
  • 2.22 Novan, Inc.
    • 2.22.1 Novan, Inc.: Total Revenue Forecast to 2028
    • 2.22.2 Novan, Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
    • 2.22.3 Novan, Inc.: Dermatological Drugs Product Pipeline, 2018
    • 2.22.4 Novan, Inc.: Recent Developments
      • 2.22.4.1 Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
      • 2.22.4.2 Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
      • 2.22.4.3 Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
  • 2.23 Bayer AG
    • 2.23.1 Bayer AG: Total Revenue Forecast to 2028
    • 2.23.2 Bayer AG: Dermatology Revenue Forecast to 2028
    • 2.23.3 Bayer AG: Dermatological Drugs Portfolio, 2018
    • 2.23.4 Global Leading Dermatological Drugs Bayer
      • 2.23.4.1 Canesten
        • 2.23.4.1.1 Canesten: Revenue Forecast to 2028
      • 2.23.4.2 Bepanthen/Bepanthol
        • 2.23.4.2.1 Bepanthen/ Bepanthol: Revenue Forecast to 2028
    • 2.23.5 Bayer AG: Recent Developments
      • 2.23.5.1 Bayer hones its brand profile
      • 2.23.5.2 Bayer combines pharmaceutical research and development unit
  • 2.24 Astellas Pharma Inc.
    • 2.24.1 Astellas Pharma Inc.: Total Revenue Forecast to 2028
    • 2.24.2 Astellas Pharma Inc.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
    • 2.24.3 Astellas Pharma Inc.: Dermatological Drugs Portfolio, 2018
    • 2.24.4 Astellas Pharma Inc.: Recent Developments
      • 2.24.4.1 Astellas Acquires Universal Cells, Inc.
  • 2.25 Pierre Fabre, S.A.
    • 2.24.1 Pierre Fabre, S.A.: Total Revenue Forecast to 2028
    • 2.24.2 Pierre Fabre, S.A.: Dermatology Revenue Forecast to 2028
    • 2.25.3 Pierre Fabre, S.A.: Dermatological Drugs Portfolio, 2018
    • 2.25.4 Pierre Fabre, S.A.: Recent Developments
      • 2.25.4.1 Pierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology
      • 2.25.4.2 PIERRE FABRE signs a partnership with biotech company SETUBIO as part of the Nature Open Library program
      • 2.25.4.3 Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK (fluorouracil) Cream 4% in the USA and beyond

3. Conclusion

Associated Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Leading Dermatological Drug Manufacturers: Total Company Revenue ($bn), 2017
  • Table 2.2 Leading Dermatological Drug Manufacturers: Dermatology Segment Revenue ($bn), 2017
  • Table 2.3 Galderma: Company Overview, 2017
  • Table 2.4 Galderma (Nestle Skin Health S.A.): Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.5 Galderma (Nestle Skin Health S.A.): Dermatology Revenue Forecast: (US$ bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.6 Epiduo: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.7 Differin: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.8 Johnson & Johnson: Company Overview, 2017
  • Table 2.9 Johnson & Johnson: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.10 Johnson & Johnson: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.11 Stelara: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.12 Remicade: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.13 AbbVie, Inc.: Company Overview, 2017
  • Table 2.14 AbbVie, Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.15 AbbVie, Inc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.16 Humira: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.17 AbbVie Inc., Dermatological Drug Pipeline, 2018
  • Table 2.18 GlaxoSmithKline, plc (GSK): Company Overview, 2017
  • Table 2.19 GlaxoSmithKline, plc (GSK): Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.20 GlaxoSmithKline, plc (GSK): Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.21 Valtrex: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.22 Lamisil: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.23 Bactroban: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.24 Dermovate: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.25 GlaxoSmithKline, plc., dermatological drug pipeline, 2018
  • Table 2.26 Pfizer, Inc.: Company Overview, 2017
  • Table 2.27 Pfizer, Inc.: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.28 Pfizer, Inc.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.29 Zyvox: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.30 Pfizer, Inc.: Dermatological Drug Pipeline, 2018
  • Table 2.31 LEO Pharma A/S: Company Overview, 2017
  • Table 2.32 LEO Pharma A/S: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.33 LEO Pharma A/S: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.34 Protopic: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.35 LeoPharmaA/S: Dermatological Drug Pipeline, 2018
  • Table 2.36 Valeant Pharmaceuticals (Bausch Health Companies Inc.): Company Overview, 2017
  • Table 2.37 Valeant Pharmaceuticals: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.38 Valeant Pharmaceuticals: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018 - 2028
  • Table 2.39 Solodyn: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.40 Ziana: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.41 Valeant Pharmaceuticals: Dermatological Drug Pipeline, 2018
  • Table 2.42 Almirall S.A.: Company Overview, 2017
  • Table 2.43 Almirall S.A.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018 - 2028
  • Table 2.44 Almirall S.A.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.45 Almirall S.A.: Dermatological Drug Pipeline, 2018
  • Table 2.46 Eli Lilly and Company: Company Overview, 2017
  • Table 2.47 Eli Lilly and Company: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.48 Eli Lilly and Company: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.49 Taltz: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.50 Eli Lilly and Company: Dermatological Drug Pipeline, 2018
  • Table 2.51 Mylan N.V.: Company Overview, 2017
  • Table 2.52 Mylan N.V.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.53 Mylan N.V.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.54 Lupin Ltd.: Company Overview, 2017
  • Table 2.55 Lupin Ltd.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.56 Lupin Ltd.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.57 Lupin Ltd: Dermatological Drug Pipeline, 2018
  • Table 2.58 Novartis AG: Company Overview, 2017
  • Table 2.59 Novartis AG: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.60 Novartis AG: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.61 Cosentyx: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.62 Novartis AG: Dermatological Drug Pipeline, 2018
  • Table 2.63 Sanofi: Company Overview, 2017
  • Table 2.64 Sanofi: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.65 Sanofi: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.66 Allergan plc.: Company Overview, 2017
  • Table 2.67 Allergan plc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.68 Allergan plc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.69 Aczone: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.70 Allergan, plc: Dermatological Drug Pipeline, 2018
  • Table 2.71 Merck: Company Overview, 2017
  • Table 2.72 Merck: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.73 Merck: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.74 Cubicin: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.75 Elocon: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.76 Sun Pharmaceutical Industries, Ltd.: Company Overview, 2017
  • Table 2.77 Sun Pharmaceutical Industries, Ltd.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.78 Sun Pharmaceutical Industries, Ltd.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.79 Absorica /Epirus: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.80 Amgen Inc.: Company Overview, 2017
  • Table 2.81 Amgen Inc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.82 Amgen Inc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.83 Enbrel: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.84 Amgen, Inc.: Dermatological Drug Pipeline, 2018
  • Table 2.85 F. Hoffmann-La Roche Ltd: Company Overview, 2017
  • Table 2.86 F. Hoffmann-La Roche Ltd: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.87 F. Hoffmann-La Roche Ltd: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.88 Mayne Pharma: Company Overview, 2017
  • Table 2.89 Mayne Pharma: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.90 Mayne Pharma: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.91 Doryx: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.92 Concert Pharmaceuticals, Inc.: Company Overview, 2017
  • Table 2.93 Concert Pharmaceuticals, Inc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.94 Concert Pharmaceuticals, Inc.: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.95 Novan, Inc.: Company Overview, 2017
  • Table 2.96 Novan, Inc.: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.97 Novan, Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.98 Novan, Inc.: Dermatological Drug Pipeline, 2018
  • Table 2.99 Bayer AG: Company Overview, 2017
  • Table 2.100 Bayer AG: Total Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.101 Bayer AG: Dermatology Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.102 Canesten: Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.103 Bepanthen/ Bepanthol: Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.104 Astellas Pharma Inc.: Company Overview, 2017
  • Table 2.105 Astellas Pharma Inc.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.106 Astellas Pharma Inc.: Dermatology Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 2.107 Pierre Fabre, S.A.: Company Overview, 2017
  • Table 2.108 Pierre Fabre, S.A.: Total Revenue Forecast: ($bn), AGR (%), CAGR (%), 2018-2028

List of Figures

  • Figure 2.1 Galderma: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.2 Galderma: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.3 Epiduo: Revenue Forecast ($bn), 2018-2028
  • Figure 2.4 Differin: Revenue Forecast ($bn), 2018-2028
  • Figure 2.5 Johnson & Johnson: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.6 Johnson & Johnson: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.7 Stelara: Revenue Forecast ($bn), 2018-2028
  • Figure 2.8 Remicade: Revenue Forecast ($bn), 2018-2028
  • Figure 2.9 AbbVie, Inc.: Revenue Forecast ($bn), 2018-2028
  • Figure 2.10 AbbVie, Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.11 Humira: Revenue Forecast ($bn), 2018-2028
  • Figure 2.12 GlaxoSmithKline, plc (GSK): Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.13 GlaxoSmithKline, plc (GSK): Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.14 Valtrex: Revenue Forecast ($bn), 2018-2028
  • Figure 2.15 Lamisil: Revenue Forecast ($bn), 2018-2028
  • Figure 2.16 Bactroban: Revenue Forecast ($bn), 2018-2028
  • Figure 2.17 Dermovate: Revenue Forecast ($bn), 2018-2028
  • Figure 2.18 Pfizer, Inc.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.19 Pfizer, Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.20 Zyvox Revenue Forecast ($bn), 2018-2028
  • Figure 2.21 LEO Pharma A/S: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.22 LEO Pharma A/S: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.23 Protopic: Revenue Forecast ($bn), 2018-2028
  • Figure 2.24 Valeant Pharmaceuticals: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.25 Valeant Pharmaceuticals: Dermatology Revenue Forecast ($bn), 2018 - 2028
  • Figure 2.26 Solodyn: Revenue Forecast ($bn), 2018-2028
  • Figure 2.27 Ziana: Revenue Forecast ($bn), 2018-2028
  • Figure 2.28 Almirall S.A.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.29 Almirall S.A.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.30 Eli Lilly and Company: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.31 Eli Lilly and Company: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.32 Taltz: Revenue Forecast ($bn), 2018-2028
  • Figure 2.33 Mylan N.V.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.34 Mylan N.V.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.35 Lupin Ltd.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.36 Lupin Ltd.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.37 Novartis AG: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.38 Novartis AG: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.39 Cosentyx: Revenue Forecast ($bn), 2018-2028
  • Figure 2.40 Sanofi: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.41 Sanofi: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.42 Allergan plc.: Total Revenue Forecast (US$ bn), 2018-2028
  • Figure 2.43 Allergan plc.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.44 Aczone: Revenue Forecast ($bn), 2018-2028
  • Figure 2.45 Merck: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.46 Merck: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.47 Cubicin: Revenue Forecast ($bn), 2018-2028
  • Figure 2.48 Elocon: Revenue Forecast ($bn), 2018-2028
  • Figure 2.49 Sun Pharmaceutical Industries, Ltd.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.50 Sun Pharmaceutical Industries, Ltd.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.51 Absorica /Epirus: Revenue Forecast ($bn), 2018-2028
  • Figure 2.52 Amgen Inc.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.53 Amgen Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.54 Enbrel Revenue Forecast: ($bn), 2018-2028
  • Figure 2.55 F. Hoffmann-La Roche Ltd: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.56 F. Hoffmann-La Roche Ltd: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.57 Mayne Pharma: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.58 Mayne Pharma: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.59 Doryx: Revenue Forecast ($bn), 2018-2028
  • Figure 2.60 Concert Pharmaceuticals, Inc.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.61 Concert Pharmaceuticals, Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.62 Novan, Inc.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.63 Novan, Inc.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.64 Bayer AG: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.65 Bayer AG: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.66 Canesten: Revenue Forecast ($bn), 2018-2028
  • Figure 2.67 Bepanthen/ Bepanthol: Revenue Forecast ($bn), 2018-2028
  • Figure 2.68 Astellas Pharma Inc.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.69 Astellas Pharma Inc.: Dermatology Revenue Forecast ($bn), 2018-2028
  • Figure 2.70 Pierre Fabre, S.A.: Total Revenue Forecast ($bn), 2018-2028
  • Figure 2.71 Pierre Fabre, S.A.: Dermatology Revenue Forecast ($bn), 2018-2028

Companies Listed

  • 23andMe, Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Ablynx NV
  • Actavis plc
  • Advent International
  • Allergan plc
  • Almirall S.A.
  • American Academy of Dermatology (AAD)
  • Amgen
  • ARMO BioSciences
  • Astellas Pharma Inc.
  • Avanir Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Calico Life Sciences LLC
  • Celgene Corporation
  • Celgene International Sarl
  • Celgene Pharmaceuticals, Inc.
  • Concert Pharmaceuticals, Inc.
  • Dermavant Sciences
  • Eli Lilly and Company
  • European Commission (EC)
  • European Medicines Agency (EMA)
  • FibroTx LLC
  • Food and Drug Administration (FDA)
  • Galapagos
  • Galderma
  • GlaxoSmithkline plc (GSK)
  • Hill Dermaceuticals, Inc.
  • Igenica Biotherapeutics
  • Janssen
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson (J&J)
  • KNOW Bio
  • L'Oréal
  • Laboratorios Almirall, S.A.
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma Group Limited
  • Meda Aktiebolag
  • Merck
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • Mylan N.V.
  • Nestlé
  • Nestle Skin Health S.A.
  • New Moon B.V.
  • Novan, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Pierre Fabre S.A.
  • Proteostasis Therapeutics, Inc.
  • Renaissance Acquisition Holdings, LLC.
  • Revance Therapeutics, Inc.
  • Rigontec
  • Roche
  • Roivant Sciences
  • Samsung BioLogics
  • Sandoz
  • SangStat
  • Sanofi
  • Stiefel Laboratories
  • Sun Pharmaceutical Industries, Ltd.
  • Taro Pharmaceuticals U.S.A Inc.
  • The University of Texas MD Anderson Cancer Center
  • Universal Cells, Inc.
  • Valeant Pharmaceuticals
  • Viralytics Limited
Back to Top